Using Dasatinib to Treat Traumatic Brain Injury

Abstract

Researchers at the University of California, Davis have developed a novel approach to treating traumatic brain injury (TBI) and other acute neurological disorders using the FDA-approved cancer drug, dasatinib.

Full Description

This invention leverages dasatinib, an FDA-approved kinase-targeted cancer drug, for the treatment of traumatic brain injury (TBI) and acute neurological disorders. By repurposing an existing drug dasatinib, this approach offers a quicker, cost-effective alternative to the lengthy and expensive process of developing new drugs. The research demonstrates that dasatinib can reduce cognitive deficits and alter kinase phosphorylation in TBI models, providing a promising therapeutic avenue for TBI patients.

Applications

• Treatment for mild, moderate, and severe traumatic brain injury. 
• Therapeutic applications in acute neurological disorders. 
• Potential use in reducing systemic inflammation and protecting the brain post-TBI.

Features/Benefits

• Cost and time-efficient drug development through repurposing. 
• Reduces risk of failure due to extensive pre-existing safety data. 
• Translates to clinical trials and healthcare integration upon FDA approval. 
• Decreases cognitive deficits post-TBI. Alters phosphorylation states of critical kinases involved in TBI pathology. 
• Lowers high costs and lengthy timelines associated with new drug development. 
• Meets need for effective TBI treatments that can quickly reach patients.

Patent Status